Table 3.

Clinical response by PE-based chemotherapy according to prior ICI therapy.

Response	Number of patients, (%)
	Pembrolizumab (n=15)	Nivolumab (n=44)
Complete response (CR)	2 (13.3)	1 (6.7)
Partial response (PR)	10 (66.7)	24 (54.5)
Stable disease (SD)	0 (0)	7 (15.9)
Progressive disease (PD)	2 (13.3)	11 (25.0)
Not evaluable (NE)	1 (6.7)	1 (2.3)
ORR (%)	12 (80.0)	25 (56.8)
DCR (%)	12 (80.0)	32 (72.7)

ORR, overall response rate; DCR, disease control rate; ORR, proportion of CR+PR; DCR, proportion of CR+PR+SD.